ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation

Wednesday, October 30, 2013

Submitted by

Source

Source Name: Annals of Oncology

Source URL: http://annonc.oxfordjournals.org/content/24/11/2854.abstract.html?etoc

Author(s)

A. Suzuki, L. Xiao, T. Taketa, K. Sudo, R. Wadhwa, M. A. Blum, H. Skinner, R. Komaki, B. Weston, J. H. Lee, M. S. Bhutani, D. C. Rice, D. M. Maru, J. Erasmus, S. G. Swisher, W. L. Hofstetter, and J. A. Ajani

This single-center study analyzed outcomes for 323 pts with esophageal adenocarcinoma who achieved a clinical CR after chemoradiotherapy to determine the prognostic value of pretreatment PET. Patients with an SUV >6 faired better with induction therapy and resection compared to definitive chemoradiotherapy. Those with an SUV <6 did equally well with either treatment regimen. PET SUV may facilitate determining whether bimodality or trimodality is optimal for patients with esophageal adenocarcinoma.